IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ODICINO, Franco Edoardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.746
EU - Europa 5.666
AS - Asia 5.164
SA - Sud America 880
AF - Africa 158
OC - Oceania 69
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 21.689
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.511
IT - Italia 2.154
SG - Singapore 1.841
CN - Cina 1.495
BR - Brasile 727
UA - Ucraina 654
HK - Hong Kong 592
DE - Germania 506
PL - Polonia 501
GB - Regno Unito 350
VN - Vietnam 317
FI - Finlandia 306
FR - Francia 263
TR - Turchia 211
RU - Federazione Russa 191
IN - India 185
IE - Irlanda 151
CH - Svizzera 143
CA - Canada 133
ES - Italia 90
ID - Indonesia 85
BD - Bangladesh 81
SE - Svezia 68
NL - Olanda 63
MX - Messico 61
AR - Argentina 59
JP - Giappone 58
AU - Australia 56
IQ - Iraq 56
ZA - Sudafrica 53
EE - Estonia 49
SA - Arabia Saudita 42
MY - Malesia 23
AT - Austria 21
EC - Ecuador 21
LT - Lituania 19
MA - Marocco 19
PH - Filippine 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 17
PK - Pakistan 17
CL - Cile 15
PE - Perù 15
PT - Portogallo 15
BE - Belgio 14
JO - Giordania 14
EG - Egitto 13
KE - Kenya 13
LI - Liechtenstein 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
DZ - Algeria 11
NP - Nepal 11
NZ - Nuova Zelanda 11
AZ - Azerbaigian 10
CO - Colombia 10
LU - Lussemburgo 10
BG - Bulgaria 9
JM - Giamaica 9
SK - Slovacchia (Repubblica Slovacca) 9
TN - Tunisia 9
BO - Bolivia 8
IL - Israele 8
KZ - Kazakistan 8
AL - Albania 7
DK - Danimarca 7
ET - Etiopia 7
KR - Corea 7
MK - Macedonia 7
PY - Paraguay 7
BH - Bahrain 6
IR - Iran 6
NG - Nigeria 6
OM - Oman 6
TH - Thailandia 6
CR - Costa Rica 5
EU - Europa 5
GH - Ghana 5
GR - Grecia 5
HN - Honduras 5
KG - Kirghizistan 5
UY - Uruguay 5
GT - Guatemala 4
LK - Sri Lanka 4
MU - Mauritius 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
UG - Uganda 4
BS - Bahamas 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
IS - Islanda 3
LV - Lettonia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
BB - Barbados 2
CM - Camerun 2
HR - Croazia 2
Totale 21.651
Salva come PNG Salva come JPEG
Città #
Ashburn 1.019
Singapore 948
Fairfield 913
Woodbridge 768
Hong Kong 584
Houston 488
Warsaw 485
Jacksonville 444
San Jose 410
Seattle 385
Wilmington 384
Chandler 344
Ann Arbor 338
Beijing 330
Cambridge 327
New York 295
The Dalles 252
Princeton 239
Los Angeles 226
Milan 196
Helsinki 172
Dearborn 168
Brescia 163
Nanjing 158
Lauterbourg 150
Dublin 147
Istanbul 141
Munich 127
Ho Chi Minh City 115
Council Bluffs 104
London 101
Des Moines 100
Dallas 97
Moscow 90
Zurich 87
Chicago 86
Rome 84
São Paulo 75
Buffalo 70
Redondo Beach 69
San Francisco 69
Shanghai 66
Hanoi 63
Boardman 60
Santa Clara 53
Shenyang 51
Nanchang 49
Tallinn 49
Jakarta 48
Toronto 44
Changsha 43
Hangzhou 42
Orem 42
Frankfurt am Main 41
Hebei 40
San Diego 40
Chennai 38
Tokyo 37
Tianjin 36
Denver 34
Stockholm 34
Turku 33
Jinan 32
Montreal 32
Johannesburg 31
Jiaxing 29
Nuremberg 29
Guangzhou 28
Poplar 28
Brooklyn 26
Kunming 25
Melbourne 24
Paris 24
Charlotte 22
Dhaka 22
Romola 22
Turin 22
Boston 20
Dong Ket 20
Lappeenranta 20
Pune 20
Phoenix 19
Washington 19
Ankara 18
Baghdad 18
Belo Horizonte 18
Manchester 18
Mexico City 18
Mumbai 17
Verona 17
Atlanta 16
Pleasanton 16
Amsterdam 15
Brasília 15
Hefei 15
Orange 15
Zhengzhou 15
Bergamo 14
Brussels 14
Madrid 14
Totale 13.478
Salva come PNG Salva come JPEG
Nome #
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study 2.610
Preeclampsia and late fetal growth restriction 383
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 354
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 328
Claudin3 is localized outside the tight junctions in human carcinomas 290
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 285
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 208
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 200
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 198
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 187
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 186
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 178
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas 177
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 176
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 174
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 172
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 168
Consolidation therapies revisited: weekly paclitaxel 167
Carcinoma of the Fallopian tube 163
Clinical and prognostic value of 18 F-FDG PET/CT in recurrent endometrial carcinoma 159
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study 157
Female Adnexal Tumor of Probable Wolffian Origin (FATWO): Case Report and Systematic Literature Review 154
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 152
Carcinoma of the corpus uteri 151
Carcinoma of the Fallopian tube 150
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 147
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 146
Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience 144
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 142
Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection 142
Early stage ovarian cancer: the Italian contribution to clinical research. An update 141
Role of HPV DNA, HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. 141
Replacement therapy for breast cancer survivors. A pilot study 140
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 139
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 136
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 136
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 136
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 135
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 135
New development of the FIGO staging system. 134
Gestational trophoblastic diseases 134
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer 134
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 133
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study 133
Interval debulking surgery in advanced epithelial ovarian cancer 133
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 132
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium 132
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 132
null 132
Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity 130
History of the FIGO cancer staging system 129
Carcinoma of the corpus uteri 129
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 129
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 128
Five-year follow-up of placental involution after abdominal pregnancy 127
Carcinoma of the cervix uteri 126
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 125
Hormone replacement therapy in breast cancer 125
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 124
Gestational trophoblastic diseases 124
Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy 124
Staging of gynecologic malignancies 123
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 123
Uterine sarcomas: a clinicopathologic study 122
Carcinoma of the ovary 122
Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology 122
Carcinoma of the ovary 121
Optimizing gemcitabine regimens in ovarian cancer. 120
Revised FIGO staging for carcinoma of the cervix. 120
Carcinoma of the vagina 120
Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 119
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 119
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens 119
Carcinoma of the cervix uteri 119
Crossover study with cisplatin or carboplatin in advanced ovarian cancer 118
Early non-compliance to ERAS in gynecological open surgery for malignancies, and post-operative complications: a multicenter, prospective, observational, cohort study 117
Ovarial cancer: best timing and applications of debulking surgery 117
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 117
Cancer in women 116
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 115
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts 114
Integrated mutational landscape analysis of uterine leiomyosarcomas 112
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 112
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy 112
Carcinoma of the vulva 111
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 111
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 110
Carcinoma of the vagina 110
Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group) 108
Delaying surgery for patients with a previous SARS-CoV-2 infection 108
Clear cell degeneration associated with endometriosis of abdominal wall after cesarean section: A case report and systematic review of literature 107
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 105
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 102
Chorionicity, birth weight discordance and neonatal morbidity in uncomplicated twin pregnancies delivered from 36 weeks 102
A strange case of pleuritic pain in the third trimester of pregnancy 101
Cold Knife Versus Carbon Dioxide for the Treatment of Preinvasive Cervical Lesion 100
Treatment of Early Cesarean Scar Pregnancy with Double Balloon Catheter: A Systematic Review of the Literature 100
Totale 16.994
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 0 0 0 0 0 0 271 136 76
2021/20221.018 64 157 6 43 3 51 105 70 48 122 96 253
2022/20232.139 159 59 207 274 229 283 67 148 193 128 211 181
2023/20242.370 177 106 201 159 209 375 137 183 361 245 45 172
2024/20253.546 42 113 96 471 307 310 324 143 392 252 657 439
2025/20266.289 683 832 447 826 728 471 1.085 348 423 446 0 0
Totale 22.172